XGN vs. DMTK, PMD, CNTG, BGLC, ENZ, PSNL, FEMY, THTX, NMTC, and VIRX
Should you be buying Exagen stock or one of its competitors? The main competitors of Exagen include DermTech (DMTK), Psychemedics (PMD), Centogene (CNTG), BioNexus Gene Lab (BGLC), Enzo Biochem (ENZ), Personalis (PSNL), Femasys (FEMY), Theratechnologies (THTX), NeuroOne Medical Technologies (NMTC), and Viracta Therapeutics (VIRX). These companies are all part of the "medical" sector.
Exagen (NASDAQ:XGN) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.
Exagen has higher revenue and earnings than DermTech. Exagen is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
Exagen has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, DermTech has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500.
Exagen has a net margin of -34.74% compared to DermTech's net margin of -659.57%. Exagen's return on equity of -70.75% beat DermTech's return on equity.
Exagen currently has a consensus target price of $7.00, suggesting a potential upside of 270.37%. DermTech has a consensus target price of $2.38, suggesting a potential upside of 316.89%. Given DermTech's higher probable upside, analysts clearly believe DermTech is more favorable than Exagen.
DermTech received 26 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 57.50% of users gave DermTech an outperform vote while only 54.05% of users gave Exagen an outperform vote.
In the previous week, Exagen had 11 more articles in the media than DermTech. MarketBeat recorded 16 mentions for Exagen and 5 mentions for DermTech. Exagen's average media sentiment score of 0.71 beat DermTech's score of 0.08 indicating that Exagen is being referred to more favorably in the media.
75.3% of Exagen shares are owned by institutional investors. Comparatively, 20.5% of DermTech shares are owned by institutional investors. 36.8% of Exagen shares are owned by company insiders. Comparatively, 5.1% of DermTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Exagen beats DermTech on 12 of the 18 factors compared between the two stocks.
Get Exagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
